These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19802973)

  • 1. Activity of ceftazidime and newer antibiotics against Gram-negative bacilli.
    Schassan HH; Fedder J
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():79-82. PubMed ID: 19802973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime: comparative in-vitro study.
    Verbist L; Verhaegen J
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():67-71. PubMed ID: 19802971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in-vitro activity of ceftazidime against clinically important pathogens.
    Knothe H; Dette GA
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.
    Neu HC
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():131-4. PubMed ID: 19810175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A; Meyran M; Huerre M
    Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
    Bremner DA
    Pathology; 1987 Jul; 19(3):274-6. PubMed ID: 3124067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new beta-lactam antibiotics and gentamicin.
    Acred P; Ryan DM; Sowa MA; Watts CM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():247-55. PubMed ID: 19802994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of ceftazidime against Gram-negative bacilli from paediatric patients.
    Nelson JD; Shelton S
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():179-81. PubMed ID: 19802983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of seven extended-spectrum cephalosporins against gram-negative bacilli from blood cultures.
    Norris SM; Guenthner SH; Wenzel RP
    J Antimicrob Chemother; 1985 Aug; 16(2):183-8. PubMed ID: 3934124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
    Acuna G; Johnston J; Young LS; Martin WJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():83-9. PubMed ID: 19810170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L; Dornbusch K; Hallander HO
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of eight antibiotics against Pseudomonas aeruginosa and infrequently isolated gram-negative bacilli.
    Chiaradia V; Pascoli L; Santini G
    Chemioterapia; 1985 Aug; 4(4):284-8. PubMed ID: 3931923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates.
    Giamarellou H; Sahin A; Chryssouli Z
    Drugs Exp Clin Res; 1987; 13(3):149-53. PubMed ID: 3622243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of ceftazidime compared with other beta-lactam antibiotics.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():57-62. PubMed ID: 19810169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro studies with ceftazidime.
    Giamarellou H; Avlami A; Matsakas V; Kosmidis J; Daikos GK
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():73-7. PubMed ID: 19802972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of BRL-36650, a novel beta-lactamase-stable penicillin, against multiply resistant gram-negative organisms.
    Verbist L
    J Antimicrob Chemother; 1986 Sep; 18(3):351-8. PubMed ID: 3095299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
    Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
    J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro activity of ceftazidime: comparison with other beta-lactam antibiotics.
    Vanhoof R; Gordts B; Coignau H; Stas G; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():63-6. PubMed ID: 19802970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.